Press Releases

July 1, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO , July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics

PDF Version
June 29, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics to be Added to Russell 2000® Index

SAN DIEGO , June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

PDF Version
June 11, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

SAN DIEGO , June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

PDF Version
June 5, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO , June 05, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

PDF Version
May 21, 2020 at 8:30 AM EDT

Summary Toggle Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc.

PDF Version
May 8, 2020 at 9:30 AM EDT

Summary Toggle Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA (LUNAR-COV19) Induces Adaptive Cellular Immunity PRNT50 Value (Titers) After LUNAR-COV19 Vaccination STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional

PDF Version 271.9 KB
May 7, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19); New preclinical data demonstrate robust immunogenicity with a single, low dose Company remains on track to begin clinical trial for COVID-19 vaccine this summer Successfully raised net of $75.5 million in secondary

PDF Version
May 4, 2020 at 3:00 PM EDT

Summary Toggle Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

SAN DIEGO , May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020 106.1 KB
May 4, 2020 at 8:39 AM EDT

Summary Toggle Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

SAN DIEGO and SOMERSET, N.J. , May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced

PDF Version
April 27, 2020 at 7:00 AM EDT

Summary Toggle Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate

100% of animals seroconverted by day 19 at a low dose (2 µg) LUNAR-COV19 remains on track to initiate human clinical trials this Summer SAN DIEGO , April 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger

PDF Version